OrphAI Therapeutics’ Post

💡 Discover AIT-101: OrphAI Therapeutics' groundbreaking treatment for ALS has now earned Orphan Drug Designation in the EU! With its unique ability to clear toxic aggregates, AIT-101 is leading the charge against ALS, offering hope to patients worldwide. https://lnkd.in/e3rTq-K6

OrphAI Therapeutics Appoints Jay Fine, PhD to Board of Directors https://lnkd.in/eBCDRbru

We have grown into a clinically focused company with a mission to bring life-saving drugs to patients with rare diseases. Our new name, OrphAI Therapeutics, echoes our progress & our legacy in leveraging AI for drug development." - Brigette Roberts, CEO of OrphAI Therapeutics. https://lnkd.in/gX5gKkVF

OrphAI Therapeutics will be at the 22nd Annual NEALS (Northeast ALS Consortium) meeting being held October 4 - 6, 2023 in Clearwater Florida. https://lnkd.in/gCPg_Mek

AI Therapeutics is now OrphAI Therapeutics Inc. This rebrand signifies our sharpened focus on developing treatments for orphan diseases. https://lnkd.in/gX5gKkVF

Exciting News! AI Therapeutics has rebranded to OrphAI Therapeutics Inc. as we further our commitment to treating rare diseases. Our new name captures our evolution & dedication to those in need. https://lnkd.in/gX5gKkVF

Our 24-week study aims to evaluate LAM-001's safety, tolerability, and efficacy in 15 adults with advanced PAH. Primary endpoints include changes in peak oxygen uptake, among other hemodynamic metrics. https://lnkd.in/gJb4fcEg

What sets LAM-001 apart? Dr. Aaron Waxman, Principal Investigator, explains: "Unlike current therapies, LAM-001 addresses the cellular remodeling that is the root cause of PAH by modulating both the mTOR and BMPR2 pathways." https://lnkd.in/gJb4fcEg

Exciting News! AI Therapeutics has initiated a Phase II study for LAM-001, a novel inhaled form of sirolimus, aimed at treating Pulmonary Arterial Hypertension (PAH) — a life-threatening condition affecting 30,000 U.S. patients. https://lnkd.in/gJb4fcEg